CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
an Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and increased the price target to $12 from $10. CytomX Therapeutics, Inc. (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment The price target hike comes against the backdrop of topline Phase 1 data on varsetatug maseatecan in third-line and later metastatic colorectal cancer. Clinical trial results showed that the candidate drug achieved a 32% objective response rate and an 84% disease control rate. The positive Phase 1 data reinforce Varseta-M's potential as a standard of care for the treatment of colorectal cancer. CytomX is to engage the FDA to discuss the initial registration path for bringing this highly innovative, first-in-class ADC to the market. The company has also initiated a Phase Ib study of Varseta-M combined with Avastin, as it also plans to start a Phase Ib/II trial that combines Avastin with chemotherapy in earlier-line colorectal cancer. CytomX Therapeutics also plans to prese
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) had its price target raised by Piper Sandler from $10.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d)".MarketBeat
CTMX
Earnings
- 3/16/26 - Miss
CTMX
Sec Filings
- 4/16/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- CTMX's page on the SEC website